[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-artery-dissection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-artery-dissection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100206702","defining-the-basis-of-fibromuscular-dysplasia-fmd-100206702",false,"NCT01967511","Defining the Basis of Fibromuscular Dysplasia (FMD)","Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study","DEFINE","Inclusion Criteria:\n\n* Patients of any age and freely willing to participate. For patients \\\u003C 18 years of age consent will be via parents.\n* Fluency in either English or Spanish.\n* Signed, informed consent\n* For FMD, SCAD or CvAD subjects - a clinical diagnosis of FMD, SCAD or CvAD with fulfillment of standard diagnostic criteria.\n* For healthy controls - no clinical features of FMD, SCAD or CvAD and absence of any major ongoing systemic disease including any condition requiring hospitalization, immune suppression, intravenous or injected medications or that result in functional impairment in the performance of activities of daily living. Healthy controls will be matched to enrolled FMD patients on the basis of gender and approximate age (within a 5 year window of another FMD subject).\n\nExclusion Criteria:\n\n* Patients who have co-morbidities which reduces life expectancy to one year.\n* Patients with any solid organ or hematological transplantation, or those in whom transplantation is considered.\n* Active autoimmune disease.\n* Illicit drug use.\n* HIV positive.\n* Prior malignancy.\n* Any other form of vascular disease, including other arteriopathy coronary artery disease or peripheral vascular disease\n* Family history of arteriopathy other than FMD, SCAD or CvAD (e.g. Ehlers-Danlos syndrome)",true,"ALL","18 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.",[26,27,28],"Fibromuscular Dysplasia","Spontaneous Coronary Artery Dissection","Cervical Artery Dissection",[30,31,32,27,28],"Cross-sectional study","Fibromuscular dysplasia","Fibroblast","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":37},"2013-10-01",{"date":41,"type":22},"2030-12",{"name":43,"class":44},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100642791","antithrombotic-treatment-strategies-in-cervical-artery-dissection-100642791","NCT07639892","Antithrombotic Treatment Strategies in Cervical Artery Dissection","Antiplatelet Versus Anticoagulation TREATment Strategies in Cervical Artery Dissection - TREAT-CAD 2 - A Multicenter, Randomized, Two-arm Parallel Group, Open-label, Blinded Endpoint, Pragmatic Trial","TREAT-CAD 2","Inclusion Criteria:\n\n* Written informed consent (according to requirements by national legislation)\n* Onset\u002Fvisualization of acute cerebral ischemia (≤ 3 days prior to randomization) attributable to CAD (either)\n\n  * CLINICAL ISCHEMIA: onset of acute ischemic stroke (including retinal infarct) or transient ischemic attack (including amaurosis fugax) attributable to CAD OR\n  * ISCHEMIA WITHOUT CORRESPONDING SYMPTOMS: visualization of acute ischemic lesion on diffusion weighted imaging attributable to CAD\n* Clinical MRI with suitable sequences for CAD diagnosis\n\n  * available OR\n  * scheduled to be performed before discharge (if not performed before enrolment)\n* Diagnosis of Cervical Artery Dissection (i.e. extracranial carotid and\u002For vertebral artery) by MRI\u002FA or CTA based on the presence of the following criteria (at least one)\n\n  * Mural hematoma OR\n  * Long tapering stenosis OR\n  * Intimal flap OR\n  * Double lumen OR\n  * Flame-like occlusion of the dissected artery\n\nExclusion Criteria:\n\n* Contraindications to either antiplatelets or oral anticoagulation therapy\n* Other indication than CAD for full dose oral anticoagulation\n* Contraindications for performance of MRI\n* Age \\\u003C 18 years\n* Female patients who are either pregnant or breastfeeding (pregnancy testing prior to start of treatment will follow the standard operating procedures of clinical routine at participating sites)\n\nThrombolysis and\u002For endovascular treatment (EVT) is\u002Fare not considered an exclusion criterion.",{"count":55,"type":22},1100,"INTERVENTIONAL",[58],"NA","The goal of this clinical randomised controlled trial is to compare two treatment strategies - antiplatelet treatment strategy versus anticoagulation treatment strategy - in patients with acute, ischemic Cervical Artery Dissection (CAD). The study population includes patients presenting with any (clinical or imaging) signs of cerebral ischemia due to CAD.\n\nThe trial aims to estimate the net effect of antiplatelet versus anticoagulation treatment strategies on the composite primary outcome including recurrent ischemic stroke, major bleeding, or vascular death at 90 days (±2 weeks) after randomization.\n\nParticipants will:\n\n* be randomly allocated to antiplatelet treatment strategy or anticoagulation treatment strategy\n* receive treatment according to assigned strategy for the study period of 90 days\n* be followed up for 90 days (±2 weeks) after randomization\n* undergo clinical assessments to monitor for stroke recurrence, bleeding events, and vascular death Participant reported outcomes will be assessed both at 90 days (±2 weeks) and 12 months (± 4 weeks) after enrolment and will also expand to measures of quality of life and mental health outcomes.",[28],"NOT_YET_RECRUITING","2026-06-06",{"date":64,"type":37},"2026-06-10",{"date":66,"type":22},"2026-07",{"date":68,"type":22},"2030-03",{"name":70,"class":44},"University Department of Geriatric Medicine FELIX PLATTER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100535921","risk-of-recurrent-cead-after-pregnancy-100535921","NCT06258109","Risk of Recurrent CeAD After Pregnancy","Long-term Risk of Recurrent Cervical Artery Dissection After Pregnancy (LONG-RECAP Study)","LONG-RECAP","Inclusion Criteria:\n\n* female\n* prior symptomatic cervical artery dissection (= index CeAD)\n* at least one long-term follow-up visit (at least 6 months after the initial event)\n* with information available on outcome events:\n* recurrent dissection\n* ischemic stroke\n* hemorrhagic stroke\n* functional outcome assessed by mRS score\n* with data on pregnancy after the initial event\n* at least 18 years old at the initial event\n\nExclusion Criteria:\n\n* Male patients\n* Age \\\u003C18 years\n* No long-term follow-up available or long-term follow-up \\\u003C 6 months after initial event\n* No data on pregnancy after initial event available","FEMALE",{"count":81,"type":22},1000,"Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.\n\nMethods: Multicentric, observational case-control study based on pooled individual patient data from several stroke centers.\n\nPrimary endpoint: Primary composite outcome measure includes the following outcomes: (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death.",[28,84],"Pregnancy Complications",[86,87],"Ischemic Stroke","Hemorrhagic Stroke","2024-12-12",{"date":90,"type":37},"2024-12-13",{"date":92,"type":37},"2023-01-01",{"date":94,"type":22},"2025-07-01",{"name":96,"class":44},"University Hospital, Basel, Switzerland",12]